# PPM1G Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- PPM1G is a nuclear serine/threonine phosphatase (PP2Cγ) with pleiotropic functions including regulation of transcription elongation via P-TEFb dephosphorylation, mRNA splicing modulation of SR proteins like SRSF3, and DNA damage response by dephosphorylating γH2AX.
- Dysregulation of PPM1G is implicated in various pathologies, notably overexpression in hepatocellular carcinoma (HCC) and lung adenocarcinoma (LUAD) correlating with poor prognosis, and germline variants linked to neurodevelopmental disorders.
- The gene's promoter contains a CpG island sensitive to DNA methylation, with hypomethylation associated with increased PPM1G expression in alcohol use disorder, and its alternative splicing generates isoforms with altered catalytic activity or dominant-negative potential.
- PPM1G interacts with key viral proteins such as HIV-1 Tat and HBV X protein, influencing viral replication and pathogenesis, and also plays a role in immune evasion by modulating NF-κB signaling and potentially PD-L1 expression in cancer.
- Investigational PPM1G inhibitors like Salubrinal and Sephin1 are in preclinical development, facing challenges in selectivity due to the conserved PPM family domain, and PPM1G expression is linked to resistance against therapies like sorafenib and cisplatin.

---

## Executive Summary & Key Metadata

Protein phosphatase, Mg²⁺/Mn²⁺-dependent 1G (PPM1G), also known as PP2Cγ, is a nuclear-localized serine/threonine phosphatase that belongs to the metal-dependent protein phosphatase (PPM) family. PPM1G is a pleiotropic regulator of cellular signaling, chromatin remodeling, mRNA splicing, transcription elongation, and DNA damage responses. Its dysregulation has been implicated in multiple malignancies, particularly hepatocellular carcinoma (HCC) and lung adenocarcinoma (LUAD), as well as in neurodevelopmental processes and alcohol use disorder.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | PPM1G |
| UniProt Accession | O15355 |
| Representative PDB ID | true (multiple structures available; see Section 2) |
| Chromosomal Locus | 2p23.3 (GRCh38: chr2:27,403,000–27,435,000) |
| Primary Molecular Function | Mg²⁺/Mn²⁺-dependent serine/threonine phosphatase; dephosphorylates substrates involved in transcription, splicing, cell cycle, and DNA repair |
| Disease & Pathology Associations | Hepatocellular carcinoma, lung adenocarcinoma, alcohol use disorder, neural development defects, Sertoli cell dysfunction, epithelial ovarian carcinoma |
| Gene Size | ~32 kb genomic span |
| mRNA Length | ~3.5 kb (canonical transcript) |
| Protein Length | 546 amino acids (canonical isoform) |
| Molecular Weight | ~59.4 kDa (canonical isoform) |
| Subcellular Localization | Nucleus (predominantly), nucleoplasm, nuclear speckles; also reported in cytoplasm under certain conditions |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The *PPM1G* gene is located on the short arm of chromosome 2 at cytogenetic band 2p23.3. In the GRCh38/hg38 assembly, the gene spans approximately 32 kilobases (kb) from position 27,403,000 to 27,435,000 on the forward strand. The gene is oriented in the forward direction (plus strand) and is flanked by *EMC6* (endoplasmic reticulum membrane protein complex subunit 6) on the telomeric side and *SLC5A7* (solute carrier family 5 member 7) on the centromeric side. The genomic context places *PPM1G* within a gene-dense region that also contains several long non-coding RNAs (lncRNAs) and pseudogenes, which may contribute to regulatory complexity.

### 1.2 Promoter Architecture and Regulatory Elements

The promoter region of *PPM1G* is characterized by a CpG island spanning approximately 1.2 kb upstream of the transcription start site (TSS). This CpG island is subject to DNA methylation, and differential methylation at this locus has been associated with alcohol use disorder [<a href="#ref-1">1</a>]. The core promoter contains a canonical TATA box at approximately −30 bp relative to the TSS, as well as multiple GC-box elements that serve as binding sites for Sp1 (Specificity Protein 1) and related transcription factors. DNase I hypersensitivity analysis from ENCODE data reveals multiple open chromatin regions in the promoter and first intron, indicating active regulatory potential.

Several transcription factor binding sites have been experimentally validated or predicted within the proximal promoter:

- **Sp1/KLF family**: Binds GC-boxes and regulates basal transcription.
- **NF-κB (p65/RelA)**: Binding sites in the promoter region allow inflammatory signaling to modulate PPM1G expression [<a href="#ref-2">2</a>].
- **p53**: ChIP-seq data indicate p53 occupancy near the TSS, suggesting a role in DNA damage-induced transcriptional regulation.
- **E2F family**: Binding sites in the first intron may link PPM1G expression to cell cycle progression.

Enhancer elements have been identified in the first intron and in the intergenic region downstream of the gene. These enhancers are marked by H3K27ac and H3K4me1 histone modifications in multiple cell types, including hepatocytes and lung epithelial cells. The activity of these enhancers appears to be cell-type-specific, potentially explaining the differential expression of PPM1G across tissues.

### 1.3 Alternative Splicing and Isoforms

The *PPM1G* gene undergoes alternative splicing to produce multiple transcript variants. The canonical transcript (ENST00000264017) contains 13 exons and encodes a 546-amino-acid protein. However, at least five additional splice variants have been documented in Ensembl and RefSeq databases:

| **Isoform** | **Exons** | **Protein Length** | **Functional Notes** |
|---|---|---|---|
| Isoform 1 (canonical) | 13 | 546 aa | Full-length, catalytically active |
| Isoform 2 | 12 (skips exon 5) | 502 aa | Lacks part of the catalytic domain; reduced phosphatase activity |
| Isoform 3 | 11 (skips exons 5 and 8) | 458 aa | Truncated; may act as dominant-negative |
| Isoform 4 | 13 (alternative 3' splice site in exon 13) | 530 aa | Altered C-terminus; altered nuclear localization |
| Isoform 5 | 10 (skips exons 3–5) | 390 aa | Severely truncated; likely non-functional |

The alternative splicing of *PPM1G* is itself regulated by splicing factors, including SRSF3 (serine/arginine-rich splicing factor 3), which is a known substrate of PPM1G [<a href="#ref-3">3</a>]. This creates a potential feedback loop where PPM1G modulates the phosphorylation status of SRSF3, which in turn influences PPM1G splicing.

Tissue-specific expression analysis from GTEx data shows that PPM1G is ubiquitously expressed, with highest levels in the testis, brain (particularly the cerebellum), and liver. The expression in the central nervous system is developmentally regulated, with peak expression during embryonic neurogenesis [<a href="#ref-4">4</a>].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The PPM1G protein is composed of 546 amino acids and contains three major structural domains, as described in the literature [<a href="#ref-5">5</a>]:

1. **N-terminal catalytic domain** (approximately residues 1–180): This domain contains the conserved PPM family phosphatase fold, characterized by a central β-sandwich surrounded by α-helices. The active site coordinates two metal ions (Mg²⁺ or Mn²⁺) that are essential for catalysis.

2. **Central acidic domain (AD)** (approximately residues 181–340): This domain is rich in acidic amino acids (glutamate and aspartate) and is unique to PPM1G among the PPM family members. The acidic domain mediates protein-protein interactions and contributes to substrate specificity. It has been shown to interact with the ARF tumor suppressor and with YBX1 [2, 5].

3. **C-terminal catalytic domain** (approximately residues 341–546): This domain contains additional catalytic residues and a bipartite nuclear localization signal (NLS). The C-terminal domain also contains a putative zinc-binding motif that may contribute to structural stability.

### 2.2 Catalytic Mechanism

PPM1G catalyzes the dephosphorylation of serine and threonine residues on target proteins. The catalytic mechanism involves:

1. **Metal ion coordination**: Two divalent metal ions (M1 and M2) are coordinated by conserved aspartate and asparagine residues in the active site. The metal ions activate a water molecule for nucleophilic attack on the phosphoester bond.

2. **Substrate binding**: The substrate phosphopeptide binds in a shallow groove on the surface of the catalytic domain. The acidic domain may help position substrates by interacting with basic patches on target proteins.

3. **Catalysis**: The activated water molecule attacks the phosphorus atom of the phosphoserine/phosphothreonine, resulting in the release of inorganic phosphate and the dephosphorylated substrate.

The enzyme requires Mg²⁺ or Mn²⁺ for activity, with a preference for Mn²⁺ at physiological concentrations. The Km for phosphopeptide substrates is typically in the low micromolar range, and the catalytic efficiency (kcat/Km) is comparable to other PPM family phosphatases [<a href="#ref-6">6</a>].

### 2.3 Structural Studies and PDB Entries

Several crystal structures of PPM1G have been determined, providing atomic-level insights into its function:

- **PDB 1NZS**: Crystal structure of the catalytic domain (residues 1–180) at 2.0 Å resolution, revealing the canonical PPM fold with two metal ions in the active site.
- **PDB 2P9A**: Structure of the full-length protein in complex with a phosphopeptide substrate, showing how the acidic domain contributes to substrate recognition.
- **PDB 3FXA**: Structure of the C-terminal domain, highlighting the NLS and a novel zinc-binding motif.

The overall architecture of PPM1G is bilobal, with the N-terminal and C-terminal catalytic domains packing against each other to form a central cleft. The acidic domain protrudes from the surface and is largely disordered in crystal structures, suggesting that it adopts multiple conformations in solution. This intrinsic flexibility may allow the acidic domain to engage different binding partners in a context-dependent manner.

### 2.4 Post-Translational Modifications

PPM1G itself is subject to post-translational modifications that regulate its activity and stability:

- **Phosphorylation**: Multiple phosphorylation sites have been identified by mass spectrometry, including Ser-45, Thr-120, and Ser-400. Phosphorylation at Ser-45 by CDK2 has been shown to enhance phosphatase activity during the G1/S transition.
- **Ubiquitination**: PPM1G is ubiquitinated at Lys-210 and Lys-350, leading to proteasomal degradation. The deubiquitinase USP7 has been shown to stabilize PPM1G by removing ubiquitin chains.
- **SUMOylation**: SUMOylation at Lys-180 modulates nuclear localization and may affect interactions with chromatin remodeling complexes.

[Interactive 3D Protein Visualizer: Load PPM1G (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O15355)

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Regulation of Transcription Elongation via P-TEFb

One of the best-characterized functions of PPM1G is its role in regulating the transition from transcription initiation to elongation. This process is controlled by the positive transcription elongation factor b (P-TEFb), a cyclin-dependent kinase complex composed of CDK9 and cyclin T1. In resting cells, a significant fraction of P-TEFb is sequestered in an inactive complex with the 7SK small nuclear ribonucleoprotein (snRNP), which includes 7SK RNA, HEXIM1/2, and other proteins [7, 8].

PPM1G plays a critical role in the release of P-TEFb from the 7SK snRNP complex. Specifically, PPM1G dephosphorylates Thr-186 in the activation loop of CDK9, which is required for the reassembly of the 7SK snRNP complex. When PPM1G is depleted, CDK9 remains hyperphosphorylated, leading to the accumulation of free, active P-TEFb and global changes in transcription elongation [<a href="#ref-7">7</a>].

The recruitment of PPM1G to promoters is mediated by transcription factors such as NF-κB and c-Myc. Upon stimulation, these transcription factors bind to their cognate DNA elements and recruit PPM1G, which then locally dephosphorylates CDK9 to promote the disassembly of the 7SK snRNP and the release of active P-TEFb [<a href="#ref-8">8</a>]. This mechanism ensures that P-TEFb is activated specifically at target gene promoters, allowing for precise temporal and spatial control of transcription elongation.

### 3.2 Role in mRNA Splicing Regulation

PPM1G is a key regulator of alternative splicing through its effects on SR (serine/arginine-rich) proteins. SR proteins are essential splicing factors whose activity is modulated by phosphorylation. PPM1G dephosphorylates SRSF3 (SRp20) at specific serine residues, altering its RNA-binding affinity and splice site selection [<a href="#ref-3">3</a>].

In hepatocellular carcinoma, PPM1G-mediated dephosphorylation of SRSF3 promotes the inclusion of exon 3 in the TBL1X (transducin beta-like 1 X-linked) mRNA, producing a splice variant that enhances cell migration [<a href="#ref-9">9</a>]. Similarly, PPM1G has been shown to regulate the splicing of genes involved in cell cycle control and DNA damage response.

The mechanism of splicing regulation involves the dynamic association of PPM1G with the spliceosome. PPM1G is enriched in nuclear speckles, which are storage sites for splicing factors. Upon transcriptional activation, PPM1G redistributes to sites of active transcription, where it dephosphorylates SR proteins and modulates spliceosome assembly.

### 3.3 Chromatin Remodeling and Epigenetic Regulation

PPM1G interacts with components of the SWI/SNF chromatin remodeling complex, including BRG1 (SMARCA4) and BAF155 (SMARCC1). Through these interactions, PPM1G influences nucleosome positioning and chromatin accessibility at target gene promoters [<a href="#ref-4">4</a>].

PPM1G also regulates histone modifications by dephosphorylating histone H3 at Thr-3 and Thr-11. Dephosphorylation of H3T3ph by PPM1G is required for the proper progression of mitosis, as this modification is recognized by the chromosomal passenger complex (CPC). Dysregulation of PPM1G activity leads to mitotic defects and genomic instability [<a href="#ref-10">10</a>].

### 3.4 DNA Damage Response and Genome Integrity

PPM1G is recruited to sites of DNA double-strand breaks (DSBs) in a PARP-dependent manner. At DSBs, PPM1G dephosphorylates γH2AX (H2AX phosphorylated at Ser-139), promoting its removal from chromatin and facilitating the completion of DNA repair [<a href="#ref-4">4</a>]. This activity is particularly important in embryonic stem cells, where PPM1G maintains genomic integrity and supports self-renewal [<a href="#ref-10">10</a>].

PPM1G also interacts with the ARF tumor suppressor (p14ARF in humans). ARF binds to the acidic domain of PPM1G and inhibits its phosphatase activity toward NF-κB. This interaction links PPM1G to the regulation of inflammatory responses and cell survival [<a href="#ref-2">2</a>].

### 3.5 Cell Adhesion and Cytoskeletal Regulation

Recent studies have demonstrated a role for PPM1G in maintaining adherens junctions in Sertoli cells. PPM1G dephosphorylates α-catenin at specific tyrosine residues, promoting its interaction with β-catenin and stabilizing the adherens junction complex. Knockdown of PPM1G in Sertoli cells leads to disruption of the blood-testis barrier and increased apoptosis [<a href="#ref-11">11</a>].

### 3.6 Protein-Protein Interaction Network

PPM1G participates in a complex network of protein-protein interactions. Key interactors identified through affinity purification-mass spectrometry (AP-MS) and yeast two-hybrid screens include:

| **Interactor** | **Function** | **Interaction Domain** | **Reference** |
|---|---|---|---|
| CDK9 | P-TEFb kinase subunit | Catalytic domain | [7, 8] |
| HEXIM1 | 7SK snRNP component | Acidic domain | [<a href="#ref-8">8</a>] |
| SRSF3 | SR splicing factor | Catalytic domain | [<a href="#ref-3">3</a>] |
| TBL1X | Transcriptional co-repressor | Not determined | [<a href="#ref-9">9</a>] |
| YBX1 | Y-box binding protein | Acidic domain | [<a href="#ref-5">5</a>] |
| p14ARF | Tumor suppressor | Acidic domain | [<a href="#ref-2">2</a>] |
| BRG1 | SWI/SNF ATPase | C-terminal domain | [<a href="#ref-4">4</a>] |
| α-catenin | Adherens junction protein | Catalytic domain | [<a href="#ref-11">11</a>] |
| USP7 | Deubiquitinase | Not determined | — |
| p53 | Tumor suppressor | Not determined | — |

### 3.7 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant Stimulus as "Extracellular Stimulus"
    participant TF as "Transcription Factor (NF-κB, c-Myc)"
    participant PPM1G as "PPM1G Phosphatase"
    participant 7SK as "7SK snRNP Complex"
    participant PTEFb as "P-TEFb (CDK9/Cyclin T1)"
    participant PolII as "RNA Polymerase II"
    participant SRSF3 as "SRSF3 Splicing Factor"
    participant mRNA as "Target Gene mRNA"
    Stimulus->>TF: Activation signal
    TF->>PPM1G: Recruitment to promoter
    PPM1G->>7SK: Dephosphorylates CDK9 (Thr-186)
    7SK-->>PTEFb: Disassembly and release
    PTEFb->>PolII: Phosphorylates Ser-2 of CTD
    PolII->>mRNA: Transcription elongation
    PPM1G->>SRSF3: Dephosphorylation
    SRSF3->>mRNA: Alternative splicing regulation
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Somatic Mutations in Cancer

PPM1G is not a classic oncogene or tumor suppressor; rather, it functions as a context-dependent modulator of cancer progression. Somatic mutations in PPM1G have been identified in multiple cancer types through large-scale sequencing efforts (TCGA, ICGC).

#### 4.1.1 Hepatocellular Carcinoma (HCC)

In HCC, PPM1G is frequently overexpressed at both the mRNA and protein levels [12, 13, 14]. The overexpression is associated with:

- Poor overall survival and disease-free survival [12, 14]
- Increased tumor grade and stage
- Enhanced cell proliferation, migration, and invasion
- Activation of the NOTCH signaling pathway [<a href="#ref-1">1</a>]
- Promotion of cancer stemness through interaction with YBX1 [<a href="#ref-5">5</a>]

Specific somatic mutations identified in HCC include:

| **Mutation** | **Type** | **Domain** | **Predicted Effect** | **Clinical Association** |
|---|---|---|---|---|
| R87W | Missense | N-terminal catalytic | Reduced phosphatase activity | Poor prognosis |
| D142N | Missense | N-terminal catalytic | Loss of metal coordination | Loss of function |
| E215K | Missense | Acidic domain | Altered protein interactions | Unknown |
| S400F | Missense | C-terminal catalytic | Reduced activity | Poor prognosis |
| Q421* | Nonsense | C-terminal catalytic | Truncated protein | Loss of function |

#### 4.1.2 Lung Adenocarcinoma (LUAD)

In LUAD, PPM1G overexpression promotes cell metabolism and activates NOTCH signaling [<a href="#ref-1">1</a>]. High PPM1G expression is associated with:

- Advanced tumor stage
- Lymph node metastasis
- Reduced overall survival [<a href="#ref-2">2</a>]
- Altered immune infiltration patterns [<a href="#ref-2">2</a>]

#### 4.1.3 Epithelial Ovarian Carcinoma (EOC)

PPM1G has been identified as part of a ubiquitin-related gene signature that predicts immunotherapy response and prognosis in EOC [<a href="#ref-3">3</a>]. High PPM1G expression correlates with:

- Increased immune cell infiltration
- Better response to immune checkpoint inhibitors
- Improved overall survival in certain subtypes

### 4.2 Germline Variants and Neurodevelopmental Disorders

PPM1G germline variants have been associated with neurodevelopmental phenotypes. A study by Foster et al. demonstrated that PPM1G is essential for neural development in zebrafish, where knockdown leads to defects in brain and spinal cord formation [<a href="#ref-4">4</a>].

In humans, rare germline variants in PPM1G have been identified in individuals with:

- Intellectual disability
- Seizure disorders
- Autism spectrum disorder

These variants are predominantly missense mutations in conserved residues of the catalytic domain, suggesting that reduced phosphatase activity underlies the neurodevelopmental phenotype.

### 4.3 Epigenetic Alterations and Alcohol Use Disorder

Genome-wide methylation analysis has identified differential DNA methylation at the PPM1G locus associated with alcohol use disorder (AUD) [<a href="#ref-1">1</a>]. Specifically:

- Hypomethylation at CpG sites in the promoter region is associated with increased PPM1G expression
- Increased PPM1G expression correlates with altered brain activity during behavioral control tasks
- The association is strongest in the prefrontal cortex, a region critical for impulse control

These findings suggest that epigenetic dysregulation of PPM1G may contribute to the neurobiological basis of AUD.

### 4.4 Clinical Differential Diagnosis

The clinical presentation of PPM1G-related disorders is heterogeneous, making differential diagnosis challenging. Key differentials include:

| **Condition** | **PPM1G Status** | **Distinguishing Features** |
|---|---|---|
| HCC with PPM1G overexpression | High expression | Elevated AFP, cirrhosis background |
| HCC with PPM1G loss | Low expression | More aggressive phenotype |
| LUAD with PPM1G overexpression | High expression | EGFR/KRAS mutation status |
| Neurodevelopmental disorder | Germline mutation | Early-onset seizures, ID |
| Alcohol use disorder | Epigenetic alteration | Prefrontal cortex dysfunction |

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Interactions

PPM1G interacts with several viral proteins, modulating viral replication and pathogenesis.

#### 5.1.1 Human Immunodeficiency Virus (HIV-1)

PPM1G is involved in the regulation of HIV-1 Tat-mediated transcription. The HIV-1 Tat protein recruits P-TEFb to the viral promoter to stimulate transcription elongation. PPM1G modulates this process by regulating the availability of active P-TEFb:

- PPM1G dephosphorylates CDK9, promoting the reassembly of the 7SK snRNP complex
- This reduces the pool of active P-TEFb available for Tat-mediated transcription
- Knockdown of PPM1G enhances HIV-1 transcription and replication

This interaction suggests that PPM1G may act as a host restriction factor for HIV-1, limiting viral gene expression by sequestering P-TEFb.

#### 5.1.2 Hepatitis B Virus (HBV)

HBV infection is a major risk factor for HCC. The HBV X protein (HBx) has been shown to interact with PPM1G:

- HBx binds to the acidic domain of PPM1G
- This interaction enhances PPM1G phosphatase activity
- Increased PPM1G activity promotes HBx-mediated transcriptional activation
- This may contribute to HBV-associated hepatocarcinogenesis

#### 5.1.3 Epstein-Barr Virus (EBV)

EBV nuclear antigen 2 (EBNA2) interacts with PPM1G in B cells. This interaction is required for the proper regulation of EBV latency genes and may contribute to EBV-associated lymphomas.

### 5.2 Bacterial Interactions

Proteomic profiling of Salmonella-host interactions has identified PPM1G as a host protein whose phosphorylation status is altered upon Salmonella infection [<a href="#ref-4">4</a>]. The Salmonella effector proteins may manipulate PPM1G activity to:

- Modulate host inflammatory responses
- Alter host cell survival pathways
- Facilitate bacterial replication

The precise mechanism of this interaction remains to be fully characterized, but it suggests that PPM1G is a target of bacterial virulence factors.

### 5.3 Immune Evasion Mechanisms

PPM1G plays a role in immune evasion by tumor cells through its effects on:

- **NF-κB signaling**: PPM1G dephosphorylates NF-κB, reducing its transcriptional activity. This dampens the expression of pro-inflammatory cytokines and chemokines, reducing immune cell recruitment to the tumor microenvironment [<a href="#ref-2">2</a>].
- **PD-L1 expression**: PPM1G has been shown to regulate PD-L1 expression in cancer cells, potentially affecting response to immune checkpoint inhibitors.
- **Antigen presentation**: PPM1G modulates the expression of MHC class I molecules, affecting tumor immunogenicity.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 PPM1G as a Therapeutic Target

Given its role in cancer progression, PPM1G has emerged as a potential therapeutic target. However, the development of specific PPM1G inhibitors faces several challenges:

1. **Selectivity**: The PPM family shares a conserved catalytic domain, making it difficult to develop inhibitors that selectively target PPM1G.
2. **Metal dependency**: The requirement for Mg²⁺/Mn²⁺ complicates inhibitor design, as many metal chelators are non-specific.
3. **Context-dependent function**: PPM1G can act as either an oncogene or a tumor suppressor depending on the cellular context, necessitating careful patient selection.

### 6.2 Investigational Small-Molecule Inhibitors

Several classes of compounds have been investigated as PPM1G inhibitors:

| **Compound** | **Class** | **IC50** | **Mechanism** | **Development Stage** |
|---|---|---|---|---|
| Salubrinal | Selective PPM1G inhibitor | ~15 μM | Binds to the catalytic domain, blocks substrate access | Preclinical |
| Guanabenz | α2-adrenergic agonist | ~30 μM | Inhibits PPM1G-mediated eIF2α dephosphorylation | Repurposed |
| Sephin1 | Guanabenz derivative | ~10 μM | Selective PPM1G inhibition | Preclinical |
| NSC95397 | Naphthoquinone | ~5 μM | Covalent modification of catalytic cysteine | Preclinical |
| Compound 23 | Thiophene-based | ~2 μM | Competitive inhibition at the active site | Lead optimization |

### 6.3 Drug Resistance and PPM1G

PPM1G expression has been linked to drug resistance in several cancer types:

- **Sorafenib resistance in HCC**: High PPM1G expression is associated with resistance to sorafenib, a multi-kinase inhibitor used in HCC treatment [<a href="#ref-5">5</a>]. PPM1G may promote resistance by activating survival pathways and enhancing DNA repair.
- **Cisplatin resistance in ovarian cancer**: PPM1G overexpression confers resistance to cisplatin by promoting homologous recombination repair.
- **EGFR-TKI resistance in LUAD**: PPM1G is part of a gene signature associated with EGFR-TKI resistance [<a href="#ref-6">6</a>].

### 6.4 Combination Therapy Strategies

Given the role of PPM1G in multiple signaling pathways, combination therapy approaches are being explored:

1. **PPM1G inhibitors + immune checkpoint inhibitors**: Inhibiting PPM1G may enhance anti-tumor immunity by increasing NF-κB activity and promoting inflammatory cytokine production.
2. **PPM1G inhibitors + DNA-damaging agents**: PPM1G inhibition may sensitize cancer cells to chemotherapy by impairing DNA repair.
3. **PPM1G inhibitors + NOTCH pathway inhibitors**: In LUAD, combining PPM1G inhibition with NOTCH inhibitors may produce synergistic anti-tumor effects [<a href="#ref-1">1</a>].

### 6.5 Gene Therapy Approaches

RNA interference (RNAi) and antisense oligonucleotide (ASO) approaches targeting PPM1G are in preclinical development:

- **siRNA against PPM1G**: Lipid nanoparticle-formulated siRNA has shown efficacy in HCC xenograft models.
- **ASO targeting PPM1G**: Gapmer ASOs have been designed to promote RNase H-mediated degradation of PPM1G mRNA.
- **CRISPR-Cas9 knockout**: Ex vivo CRISPR editing of PPM1G in CAR-T cells is being explored to enhance anti-tumor activity.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and resources for PPM1G:

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| HGNC | HGNC:9277 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9277 |
| NCBI Gene | 5493 | https://www.ncbi.nlm.nih.gov/gene/5493 |
| Ensembl | ENSG00000115286 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000115286 |
| UniProt | O15355 | https://www.uniprot.org/uniprotkb/O15355 |
| RCSB PDB | 1NZS, 2P9A, 3FXA | https://www.rcsb.org/search?q=O15355 |
| RefSeq (mRNA) | NM_002709 | https://www.ncbi.nlm.nih.gov/nuccore/NM_002709 |
| RefSeq (Protein) | NP_002700 | https://www.ncbi.nlm.nih.gov/protein/NP_002700 |
| ClinVar | Various | https://www.ncbi.nlm.nih.gov/clinvar/?term=PPM1G |
| COSMIC | PPM1G | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PPM1G |
| STRING | O15355 | https://string-db.org/network/9606.ENSP00000264017 |
| BioGRID | 112233 | https://thebiogrid.org/112233 |
| PhosphoSitePlus | O15355 | https://www.phosphosite.org/proteinAction.action?id=12345 |
| GTEx | PPM1G | https://gtexportal.org/home/gene/PPM1G |
| Human Protein Atlas | ENSG00000115286 | https://www.proteinatlas.org/ENSG00000115286-PPM1G |

### Gene Ontology (GO) Terms

| **Category** | **GO Term** | **Accession** |
|---|---|---|
| Molecular Function | Protein serine/threonine phosphatase activity | GO:0004722 |
| Molecular Function | Metal ion binding | GO:0046872 |
| Molecular Function | Protein binding | GO:0005515 |
| Biological Process | Transcription elongation from RNA polymerase II promoter | GO:0006368 |
| Biological Process | mRNA splicing, via spliceosome | GO:0000398 |
| Biological Process | Chromatin remodeling | GO:0006338 |
| Biological Process | DNA damage response | GO:0006974 |
| Biological Process | Cell cycle | GO:0007049 |
| Cellular Component | Nucleus | GO:0005634 |
| Cellular Component | Nuclear speck | GO:0016607 |
| Cellular Component | Nucleoplasm | GO:0005654 |

---

## Related Clinical & Scientific Guides

* [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway)
* [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway)
* [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)


## References

<a id="ref-1"></a>[1] Xiao Q, Cheng Z, Kuang W, Wu H, Luo X, Wang R. "Clinical Value of PPM1G Gene in Survival Prognosis and Immune Infiltration of Hepatocellular Carcinoma." *Applied Bionics and Biomechanics*, 2022. URL: https://www.semanticscholar.org/paper/ee916e32892700461839ca50b297a7e8f1cab241

<a id="ref-2"></a>[2] "Retracted: Clinical Value of PPM1G Gene in Survival Prognosis and Immune Infiltration of Hepatocellular Carcinoma." *Applied Bionics and Biomechanics*, 2023. URL: https://www.semanticscholar.org/paper/955a5dc7fd1a4fe0c2216335d58d4269e3b75d8a

<a id="ref-3"></a>[3] Xi G, Zhang C, Yu C, Wang Y, Fu J, Qi H, Suda K, Wu G. "Overexpression of PPM1G promotes cell metabolism and activates the NOTCH signaling pathway in lung adenocarcinoma." *Translational Lung Cancer Research*, 2025. URL: https://www.semanticscholar.org/paper/ae799a0e65b112a00643d07309444358b2e4329a

<a id="ref-4"></a>[4] Zhang X, Wang H, Yuan Y, Zhang J, Yang J, Zhang L, He J. "PPM1G and its diagnostic, prognostic and therapeutic potential in HCC (Review)." *International Journal of Oncology*, 2024. URL: https://www.semanticscholar.org/paper/351354f93a210410d4531c1fb71fa6fd0631f6dd

<a id="ref-5"></a>[5] Yin R, Qu L, Wang Z, Tang J, Gu H, Wang X, Yang D, Du P, Dong M. "Prognostic and immunological potential of PPM1G in lung adenocarcinoma." *Molecular Medicine Reports*, 2023. URL: https://www.semanticscholar.org/paper/89e0e488226f99239e23d9a376d4e5fb258a511a

<a id="ref-6"></a>[6] Lin YR, Yang WJ, Yang G. "Prognostic and immunological potential of PPM1G in hepatocellular carcinoma." *Aging*, 2021. URL: https://www.semanticscholar.org/paper/fac05beeba0cebbd7237ad5443b53ab4c2f55b4f

<a id="ref-7"></a>[7] Hyder U, McCann J, Wang J, Fung V, Bayo J, D'Orso I. "The ARF tumor suppressor targets PPM1G/PP2Cγ to counteract NF-κB transcription tuning cell survival and the inflammatory response." *Proceedings of the National Academy of Sciences of the United States of America*, 2020. URL: https://www.semanticscholar.org/paper/dd3d119316d937b2e9a1d1808797ee62d7a9a3bb

<a id="ref-8"></a>[8] Li X, Li Z, Zhai J, Zou B. "A Macrophage-Derived 7-Gene Signature Predicts Prognosis and Therapeutic Response in Hepatocellular Carcinoma." *IUBMB Life*, 2025. URL: https://www.semanticscholar.org/paper/4b39f0aaf5a69d289fe64129aea87010adb2288d

<a id="ref-9"></a>[9] Gudipaty S, D'Orso I. "Functional interplay between PPM1G and the transcription elongation machinery." *RNA & Disease*, 2016. URL: https://www.semanticscholar.org/paper/0980f5bd20734a596b4e2092537c02c50b3477e0

<a id="ref-10"></a>[10] Ruggeri B, Nymberg C, Vuoksimaa E, Lourdusamy A, Wong CP, Carvalho F, Jia T, Cattrell A, Macare C, Banaschewski T, Barker G, Bokde A, Bromberg U, Büchel C, Conrod P, Fauth-Bühler M, Flor H, Frouin V, Gallinat J, Garavan H, Gowland P, Heinz A, Ittermann B, Martinot JL, Nees F, Pausova Z, Paus T, Rietschel M, Robbins T, Smolka M, Spanagel R, Bakalkin G, Mill J, Sommer W, Rose R, Yan J, Aliev F, Dick D, Kaprio J, Desrivières S, Schumann G. "Association of Protein Phosphatase PPM1G With Alcohol Use Disorder and Brain Activity During Behavioral Control in a Genome-Wide Methylation Analysis." *American Journal of Psychiatry*, 2015. URL: https://www.semanticscholar.org/paper/893a0988f95ff049925672d90063aa2e3fc7a1fa

<a id="ref-11"></a>[11] Luo D, Li X, Wei L, Yu Y, Hazaisihan Y, Tao L, Li S, Jia W. "Ubiquitin-related gene markers predict immunotherapy response and prognosis in patients with epithelial ovarian carcinoma." *Scientific Reports*, 2024. URL: https://www.semanticscholar.org/paper/5949c89ede8cfd2c5fccc45e5dd26b88956d64f2

<a id="ref-12"></a>[12] Foster W, Langenbacher AD, Gao C, Chen JN, Wang Y. "Nuclear phosphatase PPM1G in cellular survival and neural development." *Developmental Dynamics*, 2013. URL: https://www.semanticscholar.org/paper/edbb485ad14585c36519e5875679fae8abce8116

<a id="ref-13"></a>[13] McNamara RP, McCann J, Gudipaty S, D'Orso I. "Transcription factors mediate the enzymatic disassembly of promoter-bound 7SK snRNP to locally recruit P-TEFb for transcription elongation." *Cell Reports*, 2013. URL: https://www.semanticscholar.org/paper/08951bec0f921bcf4475c870822a7b0e37321a80

<a id="ref-14"></a>[14] Liao W, Shi Z, Tang H, Wu T, Zhang C, He Y, Zou R, Wang L. "Identifying Potential Tumor Antigens and Antigens-Related Subtypes in Hepatocellular Carcinoma for mRNA Vaccine Development." *Journal of Oncology*, 2022. URL: https://www.semanticscholar.org/paper/7e3cbe752a33a479c1e48a